Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.
Stay up to date on recent advances in the multidisciplinary approach to cancer.